Time New York: Wed 07 Dec 05:31 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

IntelliPharmaCeutics (IPCI) Jumps: Stock Adds 5% in Session

Zacks

IntelliPharmaCeutics International Inc. IPCI was a big mover last session, as the company saw its shares rise 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.46 to $3.11 in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

IntelliPharmaCeutics International carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

INTELLIPHARMACT Price


INTELLIPHARMACT Price | INTELLIPHARMACT Quote

A better-ranked stock in the same industry is Advanced Accelerator Applications S.A. AAAP, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is IPCI going up? Or down? Predict to see what others think: Up or Down

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.